Stock listing

Ascletis Pharma, Inc.

Selected listing: A2JRKN · LS · EUR · DE

Ascletis Pharma, Inc. (Lang & Schwarz: A2JRKN), Health Technology. Latest release Oct 2, 2026: Ascletis' ASC36 35FDC Demonstrated Potential for Once-Monthly…

A2JRKN:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2JRKN
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Ascletis Pharma, Inc.

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

October 2, 2026

VOLUNTARY ANNOUNCEMENT - ASCLETIS' ASC36_35FDC DEMONSTRATED POTENTIAL FOR ONCE-MONTHLY TO ONCE-QUARTERLY DOSING AND ROBUST WEIGHT-LOSS IN PRECLINICAL STUDIES PRESENTED AT EASD 2026

October 2, 2026

Interim Report 2026

September 29, 2026

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

September 28, 2026

VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSITIVE RESULTS FROM 28-DAY PROOF-OF-CONCEPT CLINICAL STUDY IN U.S. FOR ASC50, A FIRST-IN-CLASS AND BEST-IN-CLASS ORAL SMALL MOLECULE IL-17A INHIBITOR FOR THE TREATMENT OF PLAQUE PSORIASIS

September 28, 2026

All Ascletis Pharma, Inc. news →

Research Ascletis Pharma, Inc.

Ascletis Pharma, Inc. company profile

View the public company page for Ascletis Pharma, Inc. on 6ix.

Ascletis Pharma, Inc. news

Read company news and market updates connected to Ascletis Pharma, Inc..

Ascletis Pharma, Inc. investor events

Find investor webinars, events, and replay context for Ascletis Pharma, Inc..